Detalhe da pesquisa
1.
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell;
175(4): 998-1013.e20, 2018 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30388456
2.
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell;
176(1-2): 404, 2019 Jan 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30633907
3.
Targeting TBK1 to overcome resistance to cancer immunotherapy.
Nature;
615(7950): 158-167, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36634707
4.
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med;
388(1): 44-54, 2023 01 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36546659
5.
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
Blood;
142(5): 421-433, 2023 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37146250
6.
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.
Gut;
73(4): 639-648, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38123998
7.
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
Mol Cancer;
23(1): 56, 2024 03 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38491381
8.
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Br J Cancer;
126(7): 1027-1036, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34887522
9.
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
Proc Natl Acad Sci U S A;
116(34): 16971-16980, 2019 08 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31375632
10.
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
Proc Natl Acad Sci U S A;
114(22): E4482-E4491, 2017 05 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28507152
11.
Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies.
Clin Chem;
64(12): 1762-1771, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30274976
12.
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Oncologist;
22(1): 25-32, 2017 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27789775
13.
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Oncologist;
26(8): e1483, 2021 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33978307
14.
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.
Invest New Drugs;
33(5): 1108-14, 2015 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26123926
15.
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
Lancet Oncol;
15(13): 1433-1441, 2014 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25456362
16.
Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
Clin Cancer Res;
30(9): 1934-1944, 2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38372707
17.
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
J Thorac Oncol;
19(5): 732-748, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38154514
18.
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
J Clin Oncol;
42(9): 1021-1030, 2024 Mar 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38252908
19.
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
JAMA Oncol;
10(1): 32-41, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37971722
20.
TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.
Cancer Discov;
14(5): 752-765, 2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38227896